Abbott Laboratories (ETR:ABL)
Germany
· Delayed Price · Currency is EUR | Market Cap | 198.14B |
| Revenue (ttm) | 39.18B |
| Net Income (ttm) | 12.44B |
| Shares Out | n/a |
| EPS (ttm) | 7.13 |
| PE Ratio | 15.92 |
| Forward PE | 25.25 |
| Dividend | 2.10 (1.84%) |
| Ex-Dividend Date | Apr 15, 2025 |
| Volume | 38 |
| Average Volume | 712 |
| Open | 114.82 |
| Previous Close | 113.96 |
| Day's Range | 113.58 - 114.82 |
| 52-Week Range | 90.00 - 134.14 |
| Beta | 0.74 |
| RSI | 43.16 |
| Earnings Date | Jul 16, 2025 |
About Abbott Laboratories
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism,... [Read more]
Financial Performance
In 2024, Abbott Laboratories's revenue was $41.95 billion, an increase of 4.59% compared to the previous year's $40.11 billion. Earnings were $13.35 billion, an increase of 134.19%.
Financial numbers in USD Financial StatementsNews
Abbott Labs: Proactive, Adaptive, Solid
Abbott Laboratories: FreeStyle Libre CGMs And EPD Business Driving Positive Momentum
Best Dividend Aristocrats For July 2025
Dividend Aristocrats have underperformed the S&P 500 in 2025, with NOBL up 1.77% versus SPY's 5.55% year-to-date gain. Dividend growth remains healthy, with 44 out of 69 Aristocrats already raising pa...
How Is The Market Feeling About Abbott Laboratories?
Abbott Laboratories's (NYSE: ABT) short percent of float has risen 3.45% since its last report. The company recently reported that it has 20.80 million shares sold short , which is 1.2% of all regula...
Tech stocks rally: Semiconductors lead the charge while healthcare stumbles
Sector Overview Today’s stock market heatmap presents a dynamic landscape, with technology leading the charge. The semiconductor sector shines brightly, spearheaded by Nvidia (NVDA), which is up by 1....
Abbott Hosts Conference Call for Second-Quarter Earnings
ABBOTT PARK, Ill., June 26, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its second-quarter 2025 financial results on Thursday, July 17, before the market opens.
Best Dividend Kings: June 2025
Dividend Kings have underperformed the S&P 500 year-to-date, but 26 are outperforming SPY in 2025, with 32 posting positive returns. Dividend growth remains healthy, with four recent increases and a c...
New Research on Abbott's Healthy Food Rx Program Shows 'Food is Medicine' Approach Helps People Living With Diabetes Eat Better and Feel Healthier
Randomized, controlled clinical trial presented as a late-breaking poster at ADA's Scientific Sessions shows people participating in Abbott's Healthy Food Rx ate more vegetables and fruit, and reporte...
Eaton makes a move outside of the data center plus, what's new with Abbott Labs
Every weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of trading.
Abbott Laboratories declares $0.59 dividend
Abbott Declares 406th Consecutive Quarterly Dividend
ABBOTT PARK, Ill., June 13, 2025 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 59 cents per share.
Abbott Laboratories Stock Sees RS Rating Rise To 82
A Relative Strength Rating upgrade for Abbott Laboratories shows improving technical performance.
The Highest-Quality Dividend Contenders By Quality Scores
The article presents the highest-quality Dividend Contenders, companies listed on U.S. exchanges with higher annual dividend payouts for 10-24 consecutive years. I use a quality scoring system with si...
Peering Into Abbott Laboratories's Recent Short Interest
Abbott Laboratories's (NYSE: ABT) short percent of float has risen 5.74% since its last report. The company recently reported that it has 22.26 million shares sold short , which is 1.29% of all regul...
Healthcare companies are hiring. Is it time to look for growth stocks in this beaten-down sector?
The recent jobs data showed that hiring in healthcare took a big jump in May, as the stock sector has stabilized a bit after years of underperformance.
Sainte Nutritional Files For Hong Kong IPO
The Qingdao-based maker of food for special medical purposes is challenging international firms that still dominate the China market but could face tariff uncertainties Key Takeaways: Sainte Nutrition...
Faulty prostate cancer tests leave 406 Hong Kong patients with nervy wait
Hong Kong public hospitals are reviewing blood test results of more than 400 patients after batches of a reagent were found to have quality issues that could produce false positives for prostate cance...
Best Dividend Aristocrats For June 2025
Dividend Aristocrats have slightly outperformed the S&P 500 year-to-date, despite underperforming in April and May. Dividend growth remains robust, with 41 of 69 Aristocrats announcing increases in 20...
Abbott Receives FDA Approval for Tendyne™, First-of-Its-Kind Device to Replace the Mitral Valve Without Open-Heart Surgery
The Tendyne system replaces mitral valves that are not functioning properly due to a buildup of calcium in the base of the valves, known as severe mitral annular calcification (MAC) Tendyne offers a n...
Abbott Laboratories: Why Wall Street's Skepticism Misses The Real Story
Senseonics Holdings, Inc. Announces Closing of Public Offering, Including Exercise in Full of the Underwriters' Option to Purchase Additional Shares, and Closing of Private Placement
Public offering results in gross proceeds of $57.5 million Private placement results in gross proceeds of approximately $20.3 million GERMANTOWN, Md., May 21, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdi...
Abbott India's quarterly profit climbs 28% on strong demand
Drugmaker Abbott India reported a 28% rise in fourth-quarter profit on Thursday, helped by strong demand for its gastrointestinal and anti-infective medications.
Abbott's Libre® Technology is First Continuous Glucose Monitor Associated with Reduced Hospitalizations for Heart Complications in People with Diabetes
New data reveal a 78% reduction in cardiovascular disease-related hospitalizations for people living with Type 1 diabetes with prior severe low blood sugar episodes.1 This significant decrease is link...
Recent Filing Shows That Rep. Bruce Westerman Sold Over $137K Worth of Apple Stock
An official report on May 12, 2025 reveals Representative Bruce Westerman's recent sale of Apple (NASDAQ: AAPL) stock, valued between $137,095 and $1,530,000. The transaction took place on May 12, 20...
Abbott Labs CEO on federal health care spending, investing in healthy people and weight loss drugs
Robert Ford, Abbott Labs CEO, joins 'Power Lunch' to discuss government spending on health care and technological investments.